Your browser is no longer supported. Please, upgrade your browser.
Settings
KALV [NASD]
KalVista Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own1.90% Shs Outstand17.91M Perf Week4.51%
Market Cap308.15M Forward P/E- EPS next Y-3.32 Insider Trans6.90% Shs Float16.33M Perf Month-7.60%
Income-37.10M PEG- EPS next Q-0.67 Inst Own96.20% Short Float2.34% Perf Quarter13.14%
Sales5.40M P/S57.06 EPS this Y-18.80% Inst Trans0.05% Short Ratio3.08 Perf Half Y41.61%
Book/sh3.63 P/B4.79 EPS next Y-23.40% ROA-41.80% Target Price29.86 Perf Year-2.03%
Cash/sh3.15 P/C5.51 EPS next 5Y- ROE-47.40% 52W Range5.61 - 20.21 Perf YTD-8.43%
Dividend- P/FCF- EPS past 5Y33.10% ROI-48.20% 52W High-13.97% Beta2.01
Dividend %- Quick Ratio7.60 Sales past 5Y237.50% Gross Margin- 52W Low210.26% ATR1.50
Employees56 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)49.58 Volatility9.04% 9.35%
OptionableYes Debt/Eq0.00 EPS Q/Q-75.80% Profit Margin- Rel Volume1.38 Prev Close17.18
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume124.19K Price17.39
Recom1.60 SMA20-0.29% SMA50-3.78% SMA20027.85% Volume171,642 Change1.22%
Jun-15-20Initiated H.C. Wainwright Buy $30
Jul-29-19Initiated SVB Leerink Outperform $31
Mar-20-19Initiated Needham Buy $35
Oct-30-18Initiated Jefferies Buy $30
Sep-21-18Initiated Cantor Fitzgerald Overweight
Aug-31-17Initiated BTIG Research Buy $18
Jan-11-21 09:54AM  
Dec-16-20 10:51PM  
Dec-14-20 04:05PM  
08:33AM  
Dec-10-20 07:00AM  
Nov-16-20 09:43AM  
Nov-15-20 09:46AM  
Nov-09-20 07:00AM  
Oct-15-20 07:00AM  
Oct-14-20 02:37PM  
Sep-14-20 07:00AM  
Sep-11-20 07:00AM  
Aug-27-20 11:06AM  
Aug-07-20 09:24AM  
Aug-03-20 07:30AM  
Jul-02-20 07:55AM  
Jul-01-20 07:00AM  
Jun-23-20 07:04PM  
Jun-15-20 09:57AM  
May-28-20 07:30AM  
Apr-20-20 08:42AM  
Apr-13-20 01:44PM  
Apr-09-20 07:00AM  
Apr-07-20 07:00AM  
Mar-10-20 07:30AM  
Feb-21-20 02:25PM  
10:22AM  
Feb-19-20 07:30AM  
Feb-18-20 09:46AM  
Feb-13-20 10:03AM  
Feb-12-20 09:45AM  
Feb-11-20 07:23AM  
Feb-10-20 04:30PM  
Feb-05-20 08:35AM  
Feb-04-20 08:15AM  
Feb-03-20 11:54AM  
Jan-23-20 11:44AM  
05:29AM  
Jan-21-20 08:41AM  
Jan-13-20 07:00AM  
Jan-06-20 08:29AM  
Jan-02-20 07:24AM  
Dec-12-19 07:37PM  
Dec-09-19 07:00AM  
Dec-06-19 07:42AM  
Dec-05-19 09:57AM  
Dec-03-19 07:30AM  
Nov-13-19 07:30AM  
Nov-07-19 06:08AM  
Nov-06-19 03:01PM  
Oct-21-19 06:23AM  
Oct-16-19 09:16AM  
08:39AM  
Oct-01-19 07:30AM  
Sep-26-19 07:30AM  
Sep-23-19 09:51AM  
Sep-09-19 07:30AM  
Aug-05-19 04:05PM  
Jul-17-19 06:51AM  
Jul-15-19 07:30AM  
Jul-10-19 10:27AM  
Jul-01-19 07:35AM  
Jun-27-19 12:55PM  
Jun-04-19 07:30AM  
May-30-19 07:30AM  
May-28-19 07:30AM  
May-20-19 07:30AM  
May-17-19 09:05AM  
May-16-19 09:00AM  
May-15-19 08:38AM  
May-06-19 08:11AM  
Apr-30-19 07:30AM  
Apr-22-19 07:30AM  
Apr-03-19 09:16AM  
07:30AM  
Apr-01-19 07:40AM  
Mar-27-19 07:30AM  
Mar-25-19 10:00AM  
Mar-14-19 01:07PM  
07:30AM  
Mar-13-19 08:41AM  
Mar-11-19 09:57AM  
09:55AM  
Mar-07-19 08:18AM  
Feb-25-19 07:30AM  
Feb-01-19 07:30AM  
Jan-25-19 07:50AM  
Jan-04-19 07:30AM  
Dec-23-18 10:25PM  
Dec-14-18 07:30AM  
Dec-06-18 10:30AM  
Nov-12-18 07:30AM  
Nov-06-18 07:30AM  
Oct-18-18 08:35AM  
Sep-25-18 07:30AM  
Sep-21-18 03:32PM  
Sep-19-18 07:30AM  
Sep-14-18 07:30AM  
Sep-10-18 04:01PM  
Sep-06-18 11:00AM  
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Crockett Thomas AndrewCEOJan 04Sale18.1910,000181,904185,420Jan 06 05:33 PM
Palleiko Benjamin LCFO, CBO & SecretaryDec 30Option Exercise6.743582,41332,858Jan 04 06:06 PM
Palleiko Benjamin LCFO, CBO & SecretaryDec 30Sale20.043587,17532,500Jan 04 06:06 PM
Feener Edward P.Chief Scientific OfficerNov 02Sale17.146,000102,81272,734Nov 04 05:03 PM
Cha AlbertDirectorOct 30Buy17.24115,6861,994,0681,138,179Nov 03 07:56 PM
Yea ChristopherChief Development OfficerOct 29Sale17.485,00087,39462,969Nov 02 08:01 PM
Yea ChristopherChief Development OfficerOct 21Sale18.256,044110,28267,969Oct 22 05:36 PM
Feener Edward P.Chief Scientific OfficerOct 21Sale18.319,007164,92878,734Oct 22 05:34 PM
Crockett Thomas AndrewCEOOct 21Sale18.3322,545413,247195,420Oct 22 05:33 PM
Yea ChristopherChief Development OfficerOct 20Sale17.497,942138,88674,013Oct 22 05:36 PM
Feener Edward P.Chief Scientific OfficerOct 20Sale17.487,900138,09087,741Oct 22 05:34 PM
Crockett Thomas AndrewCEOOct 20Sale17.4915,994279,778217,965Oct 22 05:33 PM
Yea ChristopherChief Development OfficerOct 16Sale17.0091415,53981,955Oct 20 02:14 PM
Feener Edward P.Chief Scientific OfficerOct 16Sale17.0099316,88195,641Oct 20 02:11 PM
Crockett Thomas AndrewCEOOct 16Sale17.011,26121,444236,959Oct 20 02:08 PM
Yea ChristopherChief Development OfficerFeb 05Sale17.101001,71082,869Feb 07 05:18 PM
Feener Edward P.Chief Scientific OfficerFeb 05Sale17.111001,71196,634Feb 07 05:17 PM
Crockett Thomas AndrewCEOFeb 05Sale17.052003,410238,220Feb 07 05:14 PM